

## Short report

## Visual cortical excitability in dementia with Lewy bodies

John-Paul Taylor, Michael Firbank and John T. O'Brien

**Summary**

Alterations in the visual system may underlie visual hallucinations in dementia with Lewy bodies (DLB). However, cortical excitability as measured by transcranial magnetic stimulation (TMS) and functional magnetic resonance imaging (fMRI) activation of lower visual areas (V1–3) to visual stimuli appear normal in DLB. We explored the relationship between TMS-determined phosphene threshold and fMRI-related visual activation and found a positive relationship between the two in controls but a negative one in DLB. This double dissociation suggests a loss of inhibition in the visual

system in DLB, which may predispose individuals to visual dysfunction and visual hallucinations.

**Declaration of interest**

None.

**Copyright and usage**

© The Royal College of Psychiatrists 2015. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) licence.

Dementia with Lewy bodies (DLB) is characterised by complex visual hallucinations. Previously, we used the threshold for eliciting phosphenes with occipital transcranial magnetic stimulation (TMS) as a measure of visual cortical excitability.<sup>1</sup> Although this threshold correlated with the severity and frequency of visual hallucinations in DLB, overall excitability was similar between DLB and controls, suggesting that early visual areas are functionally intact in DLB. This was supported by our finding of unaltered cortical activity in the early visual system (V1, V2/V3), as measured by blood oxygen level-dependent (BOLD) functional magnetic resonance imaging (fMRI), in DLB.<sup>2</sup> BOLD haemodynamic response has been suggested to be related to synaptic activity in terms of input and local processing,<sup>3</sup> as well as to neuronal spiking<sup>4</sup> arising from sensory stimulation, and thus may represent the activity in both excitatory and inhibitory neuronal populations. In contrast, the neuronal discharge consequent to TMS is likely to be dependent on the relative balance of excitatory and inhibitory activity within the area of stimulation. Therefore a positive relationship between BOLD activity in the early visual system and phosphene threshold may suggest that inhibition outweighs excitation, whereas a negative relationship may indicate the opposite. In this paper we report the interrelationship between fMRI BOLD activity in the early visual system and visual cortical excitability as measured using TMS, using previously published data from patients with DLB and hallucinations and from controls.<sup>1,2</sup>

**Method**

Details of participant selection, neuropsychological and neuropsychiatric assessment, fMRI and TMS testing are described fully elsewhere. In the current analysis, we selected participants who had undergone both fMRI and occipital TMS.<sup>1,2</sup> In brief, 16 participants who met criteria for probable DLB<sup>5</sup> and who experienced visual hallucinations at least once in the month before TMS/fMRI testing were recruited from a community-dwelling population of patients, along with 19 controls. The study was approved by the local ethics committee. The DLB diagnosis was made independently by two experienced senior clinicians.<sup>5</sup> Occipital TMS and neuroimaging evaluations were conducted within 2 weeks of each other.

TMS and imaging protocols are described in the online supplementary methods.

**Results**

The DLB and control groups were similar in terms of age, gender and visual acuity. Unified Parkinson's Disease Rating Scale (UPDRS)<sup>6</sup> motor scores were significantly higher and cognitive test and visuo-perceptual task scores significantly lower in the DLB group (online Table DS1).

Phosphenes were elicited in a similar proportion of the control (17/19, 90%) and DLB groups (14/17, 82%; Fisher exact test,  $P=0.66$ ). Across groups, phosphene thresholds were similar (control group: median 70.7%, interquartile range (IQR) = 44.0%; DLB group: median 77.2%, IQR = 36.0%, Mann–Whitney  $U$ -test 115.5,  $P=0.23$ ).

There were no differences in V1 or V2/V3 BOLD magnitude between the control and DLB groups for checkerboard stimulus (V1: control group, mean 0.41 (s.d. = 0.36); DLB group, mean 0.57 (s.d. = 0.30),  $P=0.16$ . V2/V3 control group: mean 0.68 (s.d. = 0.36); DLB group mean 0.71 (s.d. = 0.29),  $P=0.83$ ). Similarly, there were no perfusion differences in V1 (ml/100 g/min: control group, mean 33.3 (s.d. = 9.6); DLB group, mean 28.0 (s.d. = 10.5),  $P=0.20$ ) or V2/V3 (control group, mean 32.1 (s.d. = 8.4), DLB group, mean 27.0 (s.d. = 7.6),  $P=0.15$ ) between groups. However, there were significant positive correlations between the magnitude of the BOLD response (V1 and V2/V3) to the checkerboard stimulus and phosphene thresholds in the control group and a significant negative relationship in the DLB group in both V1 and V2/V3 (V1: control group,  $\rho=0.48$ ,  $P=0.04$ ; DLB group,  $\rho=-0.71$ ,  $P=0.002$ . V2/V3: control group,  $\rho=0.64$ ,  $P=0.003$ ; DLB group,  $\rho=-0.57$ ,  $P=0.02$ , online Fig. DS1). These relationships remained significant ( $P<0.05$ ) even with the removal of non-responders (i.e. those participants with a phosphene threshold greater than 100% of the stimulator output) except for phosphene threshold *v.* V2/V3 in the DLB group. In TMS responders (i.e. those experiencing phosphenes) BOLD activity was significantly lower in the control group in V1 compared with the DLB group (control group, mean 0.40 (s.d. = 0.37); DLB group, mean 0.65 (s.d. = 0.25),  $P=0.04$ ).

Differences in the slopes for the control *v.* DLB group for V1 and V2/V3 were highly significant (Fisher  $r$ -to- $z$  transformation: V1,  $z=3.78$ ,  $P<0.001$ , V2/V3,  $z=3.76$ ,  $P<0.001$ ). BOLD activity was significantly lower in V1 and trending lower in V2/V3 in those in the DLB group who were on cholinesterase inhibitors (V1: mean 0.45 (s.d. = 0.24); V2/V3: mean 0.62 (s.d. = 0.10)) compared

with those in the DLB group not taking these agents (V1: mean 0.82 (s.d.=0.28),  $P=0.02$ ; V2/V3: mean 0.88 (s.d.=0.33),  $P=0.10$ ) although phosphene thresholds were similar, as was cerebral perfusion in V1 and V2/V3 between the DLB group on and off cholinesterase inhibitors (phosphene threshold: mean 76.7% (s.d.=20.2%) *v.* 78.2% (s.d.=21.1%),  $P=0.90$ . Perfusion (ml/100g/min): V1, mean 27.1 (s.d.=9.7) *v.* 30.4 (s.d.=13.7),  $P=0.62$ ; V2/V3, mean 27.4 (s.d.=7.3) *v.* mean 25.8 (s.d.=9.4),  $P=0.73$ ). There was no association between global cognitive function in the DLB group and phosphene threshold, BOLD activity or cerebral perfusion in V1 or V2/V3 ( $P>0.13$ ).

## Discussion

We report a significant positive relationship between phosphene threshold and BOLD activity in early visual areas (V1, V2/V3) in our controls, which suggests that the greater an individual's inherent visual cortical excitability, the smaller the visual cortical activation in response to a simple checkerboard stimulus. This observation implies that individuals with sensitive visual systems need less 'activation' to an external stimulus. In contrast, the opposite relationship in DLB infers a breakdown in this dynamic. Assuming similar visual cortical neuronal populations are activated by the checkerboard and TMS, then in the controls a positive relationship between BOLD activity and phosphene threshold implies inhibition must outweigh excitation, whereas in DLB this is reversed. If the BOLD signal represents spiking excitatory neuronal activity,<sup>4</sup> then the lack of difference between groups in mean BOLD activity suggests a loss of inhibition.

There needs to be critical consideration to our interpretations; our knowledge of the underlying neuronal activity of the BOLD signal is incomplete<sup>3,7</sup> and the BOLD effect reflects not just neuronal activity but also haemodynamic coupling, which may be altered with neurodegeneration; ideally cerebrovascular reactivity would be assessed via a CO<sub>2</sub> challenge<sup>8</sup> or similar paradigm. However, we did not observe any differences in occipital perfusion between the control and DLB group, and similarly, there was no relationship between perfusion and either BOLD response or phosphene threshold. Furthermore, cognitive function in DLB was not associated with phosphene threshold or any of the neuro-imaging measures. Thus, although not providing a direct measure of cerebrovascular reactivity, these findings suggest that the early visual system in these participants with DLB was similar to controls.

From the TMS perspective, the origin of phosphene perception may not be co-localised to the visual cortex and thus the relative state of the visual cortex may be less crucial to phosphene perception, although reciprocal connections between early visual and association areas are likely to be important.<sup>9</sup> In addition, cholinergic function has been implicated in modulating visual attention and associated BOLD fMRI responses;<sup>10</sup> our observation of differences in BOLD activity between those patients with DLB taking cholinesterase inhibitors *v.* those not, supports this and fits into the broader framework of reported cholinergic receptor changes in DLB<sup>11</sup> as well as changes in occipital metabolism in individuals with DLB with hallucination amelioration treated with donepezil.<sup>12</sup>

Finally, a loss of inhibitory activity in patients might be expected to decrease phosphene threshold relative to the control group, something which was not observed. However, it is notable that for a range of phosphene thresholds, the overall BOLD response in the DLB group was larger than in the control group, significantly so for V1 after excluding TMS non-responders (whose relative level of visual cortical excitability is unclear). Hence, one could speculate that compensatory mechanisms may

be operating in patients with DLB that attempt to 'normalise' the balance of excitation/ inhibition in an underactive early visual system, in the face of 'upstream' pathology in the visual system thus leading to a maintenance of the phosphene threshold within a normative range and possibly improved bottom-up visual processing, but at the cost of increasing the risk of visual hallucination occurrence, as evidenced by our previous work linking phosphene threshold with visual hallucination frequency and severity.<sup>1</sup>

In summary, our findings of a double dissociation suggest a marked deviance in visual neuronal processing between patients with DLB who hallucinate *v.* healthy controls. Whether this represents a specific loss of inhibitory drive in the visual cortex of people with DLB and what role cholinergic function plays remains to be clarified; neurochemical post-mortem studies or novel spectroscopic imaging assessing for example gamma-aminobutyric acid-ergic tone may be helpful in this regard.

**John-Paul Taylor**, MBBS, PhD, MRCPsych, **Michael Firbank**, PhD, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne; **John T. O'Brien**, MD, FRCPsych, Department of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK

**Correspondence:** John-Paul Taylor, Institute of Neuroscience, Henry Wellcome Building for Neurology, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. Email: john-paul.taylor@ncl.ac.uk

First received 20 Apr 2014, final revision 10 Jun 2014, accepted 14 Nov 2014

## Funding

The research was funded by an Intermediate Clinical Fellowship to J.-P.T. (WT088441MA) and also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

## References

- Taylor JP, Firbank M, Barnett N, Pearce S, Livingstone A, Mosimann U, et al. Visual hallucinations in dementia with Lewy bodies: transcranial magnetic stimulation study. *Br J Psychiatry* 2011; **199**: 492–500.
- Taylor JP, Firbank MJ, He J, Barnett N, Pearce S, Livingstone A, et al. Visual cortex in dementia with Lewy bodies: magnetic resonance imaging study. *Br J Psychiatry* 2012; **200**: 491–8.
- Logothetis NK. What we can do and what we cannot do with fMRI. *Nature* 2008; **453**: 869–78.
- Lee JH, Durand R, Gradinaru V, Zhang F, Goshen I, Kim DS, et al. Global and local fMRI signals driven by neurons defined optogenetically by type and wiring. *Nature* 2010; **465**: 788–92.
- McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien J T, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. *Neurology* 2005; **65**: 1863–72.
- Fahn S, Elton R, members of the UPDRS Development Committee. *Unified Parkinson's Disease Rating Scale*. Macmillan Health Care Information, 1987.
- Logothetis NK. Bold claims for optogenetics. *Nature* 2010; **468**: E3–4; discussion E5.
- Cantin S, Villien M, Moreaud O, Tropes I, Keignart S, Chipon E, et al. Impaired cerebral vasoreactivity to CO<sub>2</sub> in Alzheimer's disease using BOLD fMRI. *Neuroimage* 2011 **58**: 579–87.
- Taylor P, Walsh V, Eimer M. The neural signature of phosphene perception. *Hum Brain Mapp* 2010; **31**: 1408–17.
- Ricciardi E, Handjaras G, Bernardi G, Pietrini P, Furey ML. Cholinergic enhancement reduces functional connectivity and BOLD variability in visual extrastriate cortex during selective attention. *Neuropharmacology* 2013; **64**: 305–13.
- O'Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, et al. Nicotinic [alpha]4[beta]2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. *Neuroimage* 2008; **40**: 1056–63.
- Satoh M, Ishikawa H, Meguro K, Kasuya M, Ishii H, Yamaguchi S. Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project. *Eur Neurol* 2010; **64**: 337–44.



## Data supplement


**Table DS1** Demographic, cognitive and motor characteristics of participants included in study<sup>a</sup>

	Control group ( <i>n</i> = 19)	Dementia with Lewy bodies group ( <i>n</i> = 16)	<i>P</i>
Age, years: mean (s.d.)	77.6 (7.1)	81.3 (5.6)	0.10
Males:females: <i>n</i>	11:8	8:8	0.74
Unified Parkinson's Disease Rating Scale, motor subscale: mean (s.d.)	0.9 (1.6)	35.0 (13.5)	<b>&lt;0.001</b>
Mini-Mental State Examination, <sup>13</sup> mean (s.d.)	29.0 (1.2)	18.7 (5.1)	<b>&lt;0.001</b>
Cambridge Cognitive Examination (CAMCOG), <sup>14</sup> mean (s.d.)			
Total score	96.5 (3.4)	63.7 (14.4)	<b>&lt;0.001</b>
Executive subscore	22.1 (3.4)	9.9 (4.5)	<b>&lt;0.001</b>
Memory subscore	23.6 (2.1)	15.4 (4.4)	<b>&lt;0.001</b>
Visual acuity, decimalised: mean (s.d.)	0.64 (0.29)	0.55 (0.26)	0.33
Visuoperceptual score, % correct: mean (s.d.)	39.8 (0.4)	30.6 (6.6)	<b>&lt;0.001</b>
Clinician Assessment of Fluctuation, <sup>15</sup> mean (s.d.)	–	8.3 (4.4)	N/A
One Day Fluctuation Assessment Scale, <sup>15</sup> mean (s.d.)	–	6.7 (4.7)	N/A
Neuropsychiatry Inventory, <sup>16</sup> hallucinations subscale: median (IQR)	–	2.5 (4.5)	N/A
On cholinesterase inhibitor, <i>n</i>	–	11	N/A
On anti-Parkinsonian medication, <i>n</i>	–	4	N/A
L-dopa dose equivalent, mg: <sup>b</sup> mean (s.d.)	–	145.8 (72)	N/A

N/A, not applicable.  
a. For comparison of data in control participants v. participants with dementia with Lewy bodies (DLB) independent student *t*-tests were used for continuous data and Pearson chi-squared for categorical data. Results in bold are significant.  
b. Calculated equivalent L-dopa dose in those in the DLB group on dopaminergic medication.

## Additional references

- 13 Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; **12**: 189–98.
- 14 Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. *Br J Psychiatry* 1986; **149**: 698–709.
- 15 Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. *Br J Psychiatry* 2000; **177**: 252–6.
- 16 Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology* 1994; **44**: 2308–14.

**Fig. DS1** Scatter plots showing phosphene threshold plotted against V1 blood oxygen level-dependent (BOLD) activity (a) and V2/V3 BOLD activity (b) in response to checkerboard stimulation in dementia with Lewy body (DLB, *n* = 16) and control (*n* = 19) groups.

Relationship between phosphene threshold and V1 BOLD activity in the control group was positive ( $\rho = 0.48$ ,  $P = 0.04$ ) and negative in the DLB group ( $\rho = -0.71$ ,  $P = 0.002$ ) and this was also the case for phosphene threshold v. V2/V3 BOLD activity (control group,  $\rho = 0.64$ ,  $P = 0.003$ ; DLB group,  $\rho = -0.57$ ,  $P = 0.02$ ). Linear fits to data (dashed – control group, solid – DLB group) are shown for illustrative purposes.

# BJPpsych

The British Journal of Psychiatry

## Visual cortical excitability in dementia with Lewy bodies

John-Paul Taylor, Michael Firbank and John T. O'Brien

*BJP* published online November 5, 2015 Access the most recent version at DOI:  
[10.1192/bjp.bp.114.152736](https://doi.org/10.1192/bjp.bp.114.152736)

---

<b>Supplementary Material</b>	Supplementary material can be found at: <a href="http://bjp.rcpsych.org/content/suppl/2015/10/15/bjp.bp.114.152736.DC1.html">http://bjp.rcpsych.org/content/suppl/2015/10/15/bjp.bp.114.152736.DC1.html</a>
<b>References</b>	This article cites 0 articles, 0 of which you can access for free at: <a href="http://bjp.rcpsych.org/content/early/2015/10/12/bjp.bp.114.152736#BIBL">http://bjp.rcpsych.org/content/early/2015/10/12/bjp.bp.114.152736#BIBL</a>
<b>Reprints/permissions</b>	To obtain reprints or permission to reproduce material from this paper, please write to <a href="mailto:permissions@rcpsych.ac.uk">permissions@rcpsych.ac.uk</a>
<b>P&lt;P</b>	Published online 2015-11-05T00:05:17-08:00 in advance of the print journal.
<b>You can respond to this article at</b>	<a href="/letters/submit/bjprcpsych;bjp.bp.114.152736v1">/letters/submit/bjprcpsych;bjp.bp.114.152736v1</a>
<b>Downloaded from</b>	<a href="http://bjp.rcpsych.org/">http://bjp.rcpsych.org/</a> on November 23, 2015 Published by The Royal College of Psychiatrists

---

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

---

To subscribe to *The British Journal of Psychiatry* go to:  
<http://bjp.rcpsych.org/site/subscriptions/>

---